BAY 2666605

Research use only, not for human use.

BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.

BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.(In Vitro):BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer.(In Vivo):In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy.

——

——

——

Angiogenesis

PDE

Wnt

——

——

2275774-60-0

352.28

C17H12F4N2O2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (709.66 mM)

C[C@@H]1OC(=O)NN=C1C1=CC=C(C2=CC=C(F)C=C2)C(=C1)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years